1. Assessing New Paradigms in CLL: MRD Negativity

3. Response Criteria per the 2008 iwCLL Guidelines

4. Defining MRD Negativity

5. Importance of Reviewing MRD

6. MRD Negativity Rates of Different Therapies When Given in the Front Line

7. CLL8 Trial: Significant Impact of MRD on PFS and OS

10. FCR in Patients With R/R CLL: MRD Negativity

11. CLL206 Trial: Alemtuzumab in CLL Patients With Del(17p) and Prognostic Impact of BM MRD-Negativity

12. CR Rates With BCR Signaling Inhibitors

13. Helios Study: MRD Negativity With Ibrutinib Plus BR

14. Venetoclax Monotherapy in Ultra-High Risk R/R CLL With Del(17p): MRD Negativity

15. Venetoclax Plus BR in Patients With R/R or Previously Untreated CLL

16. Venetoclax Plus Rituximab in Patients With R/R CLL: Phase 1b Long-Term Data

17. MRD: A Deeper Level of Response

18. The Prognostic Value of MRD Is Independent of Other Prognostic Markers

19. Patient 1: Male Born in 1934

20. Patient 1: Male Born in 1934 (cont)

21. Patient 2: Male Born in 1940

22. Patient 2: Male Born in 1940 (cont)

23. MRD-Guided Treatment in Clinical Practice?

24. EMA: MRD as a Surrogate Endpoint for PFS

25. MRD as a Surrogate Endpoint in Clinical Trials or in Clinical Practice?

26. Patients With Faster Regrowth Have a Shorter Time to Progression

27. Phase 3 CLLM1 Study Design: Lenalidomide as Maintenance in High-Risk CLL

28. NCRI CLL8 (GALACTIC): Obinutuzumab Consolidation

29. PFS According to MRD/Therapy Groups

30. Durable Remission and Effective Retreatment With Venetoclax Plus Rituximab in R/R CLL

31. Durable Remission and Effective Retreatment with Venetoclax plus Rituximab in R/R CLL (cont)

32. Moving Forward With MRD in CLL

33. Conclusions

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)